In this study, we have examined whether the platelet Fc-receptor, Fcga
mmaRII (CD32), is associated with either of the two major platelet mem
brane glycoproteins, the GPIb-IX complex and the GPIIb-IIIa complex. M
onoclonal and polyclonal anti-GPIb-IX complex antibodies inhibited to
only a moderate degree (< 40%) the binding of the anti-FcgammaRII mono
clonal antibody, IV.3, to platelets. In contrast, 6 of 12 anti-GPIIb-I
IIa monoclonal antibodies and a polyclonal, affinity-purified rabbit a
nti-GPIIb-IIIa antibody strongly cross-blocked the binding of IV.3 to
platelets. This inhibition was dependent upon the Fab-mediated binding
of these antibodies to the GPIIb-IIIa complex since they did not inhi
bit the binding of IV.3 to Glanzmann's thrombasthenic platelets which
have normal levels of FcgammaRII but lack the GPIIb-IIIa complex. The
anti-GPIIb-IIIa monoclonal antibodies, AP3 and VM16a, had no effect on
platelet aggregation induced by ADP or thrombin but inhibited Fc-rece
ptor-dependent platelet aggregation as induced by either acetone-aggre
gated human IgG or by activating monoclonal antibodies against GPIV, P
TA1 or CD9. F(ab')2 fragments of these two anti-GPIIb-IIIa monoclonal
antibodies also inhibited Fc-receptor-dependent platelet aggregation i
ndicating that the observed interference by intact antibody was not du
e to the direct interaction of the Fc-portion of the antigen-antibody
complex with FcgammaRII. In addition, the inhibitory anti-GPIIb-IIIa a
ntibodies cross-blocked the binding of IV.3 to platelets at 0-degrees-
C as well as at 22-degrees-C suggesting that the observed inhibition w
as not dependent on the lateral mobility of either GP IIb-IIIa or Fcga
mmaRII in the platelet membrane. The combined results therefore strong
ly suggest that the platelet Fc-receptor, FcgammaRII, is topographical
ly associated with the GPIIb-IIIa complex in the intact platelet membr
ane.